SYFOVRE, for the Treatment of Dry Macular Degeneration

SYFOVREâ„¢ (pegcetacoplan injection)  has been approved by the U.S. Food & Drug Administration (FDA) for people with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a leading cause of devastating central vision loss in people over 55 in developed countries. The newly approved therapy is the first ever approved by the FDA for GA. …

SYFOVRE, for the Treatment of Dry Macular Degeneration Read More »